Cargando…
Identifying Cancers Impacted by CDK8/19
CDK8 and CDK19 Mediator kinases are transcriptional co-regulators implicated in several types of cancer. Small-molecule CDK8/19 inhibitors have recently entered or are entering clinical trials, starting with breast cancer and acute myeloid leukemia (AML). To identify other cancers where these novel...
Autores principales: | Roninson, Igor B., Győrffy, Balázs, Mack, Zachary T., Shtil, Alexander A., Shtutman, Michael S., Chen, Mengqian, Broude, Eugenia V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721656/ https://www.ncbi.nlm.nih.gov/pubmed/31382571 http://dx.doi.org/10.3390/cells8080821 |
Ejemplares similares
-
Role of transcription-regulating kinase CDK8 in colon cancer metastasis
por: Liang, Jiaxin, et al.
Publicado: (2019) -
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
por: Ding, Xiaokai, et al.
Publicado: (2022) -
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
por: McDermott, Martina S.J., et al.
Publicado: (2017) -
Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay
por: Li, Jing, et al.
Publicado: (2019) -
Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition
por: Chen, Mengqian, et al.
Publicado: (2019)